Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Women's Health Rheumatology Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial Active — Not Recruiting Non-phase study NCT07840066

Probiotics in Wellbeing

Probiotics in Wellbeing — Active Not Recruiting • Non-phase study • Diabetes / Metabolic • NCT07840066.

📅 24 Sep 2026 ⏱ 2 min read
Active — Not Recruiting
Check the registry for current status and eligibility criteria.
Status
Active — Not Recruiting
Phase
Non-phase study
NCT ID
NCT07840066
Start
2026-09-01
Completion
2027-08-01
ClinicaliQ Trial Snapshot
  • Probiotics in Wellbeing — Active Not Recruiting • Non-phase study • Diabetes / Metabolic • NCT07840066.
  • Daily probiotic supplement for 12 weeks may reduce inflammation and improve wellbeing in healthy adults.

Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

This study will investigate whether taking a probiotic supplement every day for 12 weeks can reduce low-level inflammation and improve wellbeing in generally healthy adults. Forty adults will be randomly assigned to receive either a probiotic capsule or a placebo capsule that looks the same but does not contain probiotic bacteria. Neither the participants nor the researchers involved in the study will know which treatment each participant receives until the study is completed. Participants will attend a study visit before starting the supplement and another visit after 12 weeks, with…

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Tirzepatide for Managing Overweight and Obesity (NICE TA1026)
Diabetes / Metabolic · 27 Mar 2026
Prescribe tirzepatide to adults with BMI ≥35 kg/m² or BMI 30–34.9 kg/m² with weight-related comorbidities, initiating treatment in specialist weight management services…
View guideline →
Guideline
Semaglutide for Managing Overweight and Obesity (NICE TA875)
Diabetes / Metabolic · 27 Mar 2026
Initiate semaglutide only in specialist obesity services or via shared care with clear primary-secondary care protocols for adults with BMI ≥30 kg/m²…
View guideline →
Clinical Brief
Weekly type 2 diabetes jab could replace daily injections
Diabetes / Metabolic · BBC Health · 20 Aug 2026
Weekly insulin injections (icodec) offer potential to improve adherence by reducing dosing frequency from daily to once-weekly for type 2 diabetes patients…
View brief →
Guideline
Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes
Diabetes / Metabolic · 09 Jul 2026
Teplizumab is recommended for people aged 8 years and over with stage 2 type 1 diabetes to delay progression to stage 3;…
View guideline →
Clinical Brief
Rybelsus ® (semaglutide tablets): transition to new formulation and risk of medication error
Diabetes / Metabolic · MHRA · 17 Dec 2025
Rybelsus ® (semaglutide tablets): transition to new formulation and risk of med...
View brief →
Clinical Brief
GLP-1 receptor agonists: reminder of the potential side effects and to be aware of the potential for misuse
Diabetes / Metabolic · MHRA · 24 Oct 2024
Healthcare professionals are reminded to inform patients about the common and serious side effects associated with glucagon-like peptide-1 receptor agonists (GLP-1RAs). This…
View brief →